Casdatifan showed superior efficacy in mPFS and ORR for late-line metastatic ccRCC patients compared to existing HIF-2a inhibitors and TKIs. The pooled analysis revealed a median progression-free ...
Casdatifan data were better on every efficacy measure evaluated, across all four monotherapy cohorts (n=121) of the Phase 1/1b ARC-20 study in late-line metastatic kidney cancer, relative to published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback